Suggest people have a read of this and digest it......
https://pink.citeline.com/PS147548/US-FDAs-Use-Of-CRLs-Hit-A-High-Note-In-2022-One-Third-Of-Novel-Agent-Decisions-Were-Not-Approvals
The 2022 CRLs for novel agents were almost split between letters citing clinical concerns and letters citing quality issues (11 CRLs focused on clinical topics, 8 focused on quality and one is undisclosed). However, the road ahead appears rockier for the clinical cohort than the quality CRLs.
Where will we be in 12 months time?, page-87
-
- There are more pages in this discussion • 169 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.5¢ |
Change
-0.020(4.94%) |
Mkt cap ! $698.4M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 40.0¢ | 38.0¢ | $3.442M | 8.886M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 26467 | 38.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 135324 | 3 |
View Market Depth
| Last trade - 16.10pm 18/09/2024 (20 minute delay) ? |
| BOT (ASX) Chart |